Dren Bio

Dren Bio is a clinical-stage biopharmaceutical company based in Foster City, California, focused on the discovery and development of novel antibody therapeutics that selectively deplete pathogenic cells and other disease-causing agents. Its proprietary Targeted Myeloid Engager and Phagocytosis Platform is a multispecific, antibody-based technology designed to induce potent depletion of disease-causing agents by engaging a novel phagocytic receptor selectively expressed on myeloid cells. The pipeline spans two first-in-class clinical-stage programs (including DR-01 and DR-0202) plus multiple preclinical and discovery-stage programs across oncology, autoimmune disease, immunology, and neurology. Dren Bio has established strategic collaborations with Pfizer and Sanofi, the latter of which acquired its DR-0201 (SAR448501) bispecific myeloid cell engager program. The company was surfaced as a portfolio company of 8vc and added to the API Evangelist network. It publishes no public API or developer surface; this profile captures its identity and public web properties.

Dren Bio is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Biotechnology, Antibody Therapeutics, and Oncology.

Dren Bio’s developer surface includes support, engineering blog, and 4 more developer resources.

🌐 Visit website 📡 Source on GitHub

12.3/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiopharmaceuticalBiotechnologyAntibody TherapeuticsOncologyAutoimmuneImmunologyNeurologyDrug Development

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 12.3/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 1.3 / 20

Commercial Clarity 4.2 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/dren-bio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

TermsOfService

TermsOfService

Company 2

The organization behind the API

Website

Website

Blog

Blog

Source (apis.yml)

aid: dren-bio
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/dren-bio.png
name: Dren Bio
description: Dren Bio is a clinical-stage biopharmaceutical company based in Foster City, California, focused on the discovery
  and development of novel antibody therapeutics that selectively deplete pathogenic cells and other disease-causing agents.
  Its proprietary Targeted Myeloid Engager and Phagocytosis Platform is a multispecific, antibody-based technology designed
  to induce potent depletion of disease-causing agents by engaging a novel phagocytic receptor selectively expressed on myeloid
  cells. The pipeline spans two first-in-class clinical-stage programs (including DR-01 and DR-0202) plus multiple preclinical
  and discovery-stage programs across oncology, autoimmune disease, immunology, and neurology. Dren Bio has established strategic
  collaborations with Pfizer and Sanofi, the latter of which acquired its DR-0201 (SAR448501) bispecific myeloid cell engager
  program. The company was surfaced as a portfolio company of 8vc and added to the API Evangelist network. It publishes no
  public API or developer surface; this profile captures its identity and public web properties.
url: https://raw.githubusercontent.com/api-evangelist/dren-bio/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- 8vc
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Biopharmaceutical
- Biotechnology
- Antibody Therapeutics
- Oncology
- Autoimmune
- Immunology
- Neurology
- Drug Development
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://drenbio.com
- type: Support
  url: https://www.drenbio.com/contact.html
- type: Blog
  url: https://www.drenbio.com/news.html
- type: PrivacyPolicy
  url: https://www.drenbio.com/privacy.html
- type: TermsOfService
  url: https://www.drenbio.com/termsofuse.html
- type: DomainSecurity
  url: security/dren-bio-domain-security.yml
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence